Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

The Cannigma

DECEMBER 12, 2022

What is microdosing? A microdose is a dose that does not elicit a perceivable intoxicating or trip-like effect. At most, a mood boost should be all that is felt, and if any visual or auditory effects are noticeable then the dose is not, by definition, a microdose. Everyone is different.

History 119

History Microdosing Research and Development Clinical Trials 119

CannaMD

OCTOBER 7, 2019

Analyzing a collection of similar research, Cannabis and Cannabinoid Research summarizes: Across these studies, on average, cannabis users consumed an additional 834?calories/day As counterintuitive as it might sound, this conclusion is actually in line with a growing number of studies. calories/day relative to nonusers.

Marijuana 105

Marijuana Cannabinoids Patients Conditions 105

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Rick Doblin, Ph.D, in/rickdoblin/ [link]. a leading biotech company in the hemp and cannabis industries. in/ronanlevy/. The Third Wave.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51